Progress in the study of redifferentiation therapy for radioactive iodine-refractory differentiated thyroid carcinoma

doi:10.3760/cma.j.cn371439-20231008-00076

Abstract

Abstract:

The overall prognosis of differentiated thyroid cancer is good， but a small number of patients will still develop local recurrence and distant metastasis， and lose iodine uptaking ability in the initial or treatment process， becoming radioactive iodine-refractory differentiated thyroid carcinoma （RAIR-DTC）， with a poor prognosis. Treatment options for RAIR-DTC patients are limited with poor results， and restoration of iodine uptaking capacity in RAIR-DTC through pharmacological promotion of redifferentiation is one of the important strategies for treatment.

Key words: Iodine radioisotopes, Thyroid neoplasms, Cell dedifferentiation, Molecular targeted therapy

Liu Jing, Zhang Jun. Progress in the study of redifferentiation therapy for radioactive iodine-refractory differentiated thyroid carcinoma[J]. Journal of International Oncology, 2024, 51(7): 464-467.

References 24

[1]	Haymart MR. Progress and challenges in thyroid cancer management[J]. Endocr Pract, 2021, 27(12): 1260-1263. DOI: 10.1016/j.eprac.2021.09.006.
[2]	Filetti S, Durante C, Hartl D, et al. Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol, 2019, 30(12): 1856-1883. DOI: 10.1093/annonc/mdz400. pmid: 31987292
[3]	Liu JR, Liu YQ, Lin YS, et al. Radioactive iodine-refractory differentiated thyroid cancer and redifferentiation therapy[J]. Endocrinol Metab (Seoul), 2019, 34(3): 215-225. DOI: 10.3803/EnM.2019.34.3.215.
[4]	Singh A, Ham J, Po JW, et al. The genomic landscape of thyroid cancer tumourigenesis and implications for immunotherapy[J]. Cells, 2021, 10(5): 1082. DOI:10.3390/cells10051082.
[5]	Riesco-Eizaguirre G, Santisteban P, De la Vieja A. The complex regulation of NIS expression and activity in thyroid and extrathyroidal tissues[J]. Endocr Relat Cancer, 2021, 28(10): T141-T165. DOI: 10.1530/ERC-21-0217.
[6]	Cazarin J, Dupuy C, Pires de Carvalho D. Redox homeostasis in thyroid cancer: implications in Na⁺/I^- symporter (NIS) regulation[J]. Int J Mol Sci, 2022, 23(11): 35682803. DOI: 10.3390/ijms23116129.
[7]	Oh JM, Ahn BC. Molecular mechanisms of radioactive iodine refractoriness in differentiated thyroid cancer: impaired sodium iodide symporter (NIS) expression owing to altered signaling pathway activity and intracellular localization of NIS[J]. Theranostics, 2021, 11(13): 6251-6277. DOI: 10.7150/thno.57689. pmid: 33995657
[8]	Hu JW, Yuan IJ, Mirshahidi S, et al. Thyroid carcinoma: phenotypic features, underlying biology and potential relevance for targeting therapy[J]. Int J Mol Sci, 2021, 22(4): 1950. DOI:10.3390/ijms22041950.
[9]	Cai X, Wang R, Tan J, et al. Mechanisms of regulating NIS transport to the cell membrane and redifferentiation therapy in thyroid cancer[J]. Clin Transl Oncol, 2021, 23(12): 2403-2414. DOI: 10.1007/s12094-021-02655-0. pmid: 34100218
[10]	Dunn LA, Sherman EJ, Baxi SS, et al. Vemurafenib redifferentiation of BRAF mutant, RAI-refractory thyroid cancers[J]. J Clin Endocrinol Metab, 2019, 104(5): 1417-1428. DOI:10.1210/jc.2018-01478. pmid: 30256977
[11]	Ho AL, Dedecjus M, Wirth LJ, et al. Selumetinib plus adjuvant radioactive iodine in patients with high-risk differentiated thyroid cancer: a phase Ⅲ, randomized, placebo-controlled trial (ASTRA)[J]. J Clin Oncol, 2022, 40(17): 1870-1878. DOI: 10.1200/JCO.21.00714.
[12]	Jaber T, Waguespack SG, Cabanillas ME, et al. Targeted therapy in advanced thyroid cancer to resensitize tumors to radioactive iodine[J]. J Clin Endocrinol Metab, 2018, 103(10): 3698-3705. DOI: 10.1210/jc.2018-00612. pmid: 30032208
[13]	Iravani A, Solomon B, Pattison DA, et al. Mitogen-activated protein kinase pathway inhibition for redifferentiation of radioiodine refractory differentiated thyroid cancer: an evolving protocol[J]. Thyroid, 2019, 29(11): 1634-1645. DOI: 10.1089/thy.2019.0143. pmid: 31637953
[14]	Leboulleux S, Do Cao C, Zerdoud S, et al. A phase Ⅱ redifferentiation trial with dabrafenib-trametinib and ¹³¹I in metastatic radioactive iodine refractory BRAF p.V600E-mutated differentiated thyroid cancer[J]. Clin Cancer Res, 2023, 29(13): 2401-2409. DOI: 10.1158/1078-0432.CCR-23-0046.
[15]	Tchekmedyian V, Dunn L, Sherman E, et al. Enhancing radioiodine incorporation in BRAF-mutant, radioiodine-refractory thyroid cancers with vemurafenib and the anti-ErbB3 monoclonal antibody CDX-3379: results of a pilot clinical trial[J]. Thyroid, 2022, 32(3): 273-282. DOI: 10.1089/thy.2021.0565. pmid: 35045748
[16]	National Cancer Institute (NCI). Dabrafenib and lapatinib in treating patients with refractory thyroid cancer that cannot be removed by surgery[EB/OL]. (2023-09-20) [2023-12-21]. https://classic.clinicaltrials.gov/ct2/show/NCT01947023.
[17]	Nikitski AV, Condello V, Divakaran SS, et al. Inhibition of ALK-signaling overcomes STRN-ALK-induced downregulation of the sodium iodine symporter and restores radioiodine uptake in thyroid cells[J]. Thyroid, 2023, 33(4): 464-473. DOI: 10.1089/thy.2022.0533.
[18]	Song J, Qiu W, Deng X, et al. A somatic mutation of RasGRP3 decreases Na⁺/I^- symporter expression in metastases of radioactive iodine-refractory thyroid cancer by stimulating the Akt signaling pathway[J]. Am J Cancer Res, 2018, 8(9): 1847-1855.
[19]	Hanna GJ, Busaidy NL, Chau NG, et al. Genomic correlates of response to everolimus in aggressive radioiodine-refractory thyroid cancer: a phase Ⅱ study[J]. Clin Cancer Res, 2018, 24(7): 1546-1553. DOI: 10.1158/1078-0432.CCR-17-2297.
[20]	Zhang K, Li C, Liu J, et al. DNA methylation alterations as therapeutic prospects in thyroid cancer[J]. J Endocrinol Invest, 2019, 42(4): 363-370. DOI: 10.1007/s40618-018-0922-0. pmid: 29992502
[21]	Fu H, Cheng L, Sa R, et al. Combined tazemetostat and MAPKi enhances differentiation of papillary thyroid cancer cells harbou-ring BRAF^V600E by synergistically decreasing global trimethylation of H3K27[J]. J Cell Mol Med, 2020, 24(6): 3336-3345. DOI: 10.1111/jcmm.15007.
[22]	Wächter S, Damanakis AI, Elxnat M, et al. Epigenetic modifications in thyroid cancer cells restore NIS and radio-iodine uptake and promote cell death[J]. J Clin Med, 2018, 7(4): 61. DOI:10.3390/jcm7040061.
[23]	Groener JB, Gelen D, Mogler C, et al. BRAF^V600E and retinoic acid in radioiodine-refractory papillary thyroid cancer[J]. Horm Metab Res, 2019, 51(1): 69-75. DOI: 10.1055/a-0765-9078.
[24]	Pak K, Shin S, Kim SJ, et al. Response of retinoic acid in patients with radioactive iodine-refractory thyroid cancer: a meta-analysis[J]. Oncol Res Treat, 2018, 41(3): 100-104. DOI: 10.1159/000484206. pmid: 29485411